Securities Complaint Against Pfizer Dismissed

     MANHATTAN (CN) – A federal judge has dismissed a class-action securities complaint against Pfizer, whose share price dropped by 11 percent after it suspended testing of its anti-cholesterol drug torcetrapib late in 2006.

     Judge Lewis Kaplan found that lead plaintiffs the Uniformed Sanitationmen’s Association Accrual Fund “have not pleaded with particularity facts sufficient to support their allegation that defendants’ statements were materially misleading.”

%d bloggers like this: